{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"48.14","spread":"34.2","upperLimit":"63.06","value":"123"},{"groupId":"OG001","lowerLimit":"82.28","spread":"64.5","upperLimit":"105.21","value":"170"},{"groupId":"OG002","spread":"58.4","value":"215"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"12"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Treatment Arm, bortezomib 1.3 mg/m\\^2 IV bolus on days 1, 4, 8, 11 over a 21-day treatment cycle, rifampicin 600 mg oral tablet once daily days 4 to 10 in cycle 3.","id":"OG000","title":"VELCADE + Rifampicin"},{"description":"Treatment arm, bortezomib 1.3 mg/m\\^2 IV bolus on days 1, 4, 8, 11 over a 21-day treatment cycle, dexamethasone 40 mg oral tablet once daily days 1 to 4, and 9 to 12 in cycle 3.","id":"OG001","title":"VELCADE + Dexamethasone"},{"description":"Control arm, bortezomib 1.3 mg/m\\^2 IV bolus on days 1, 4, 8, 11 over a 21-day treatment cycle.","id":"OG002","title":"VELCADE"}],"paramType":"MEAN","populationDescription":"Pharmacokinetic (PK) evaluable population, include all subjects completed 3 cycles of treatment and all PK assessments during the first 3 cycles of the study.","reportingStatus":"POSTED","timeFrame":"Cycle 3 day 14 (72 hours post last dose)","title":"Area Under the Plasma Concentration-time Curve (AUC) 0-72 Hours","type":"PRIMARY","unitOfMeasure":"ng*h/mL"}